Laurus Labs Falls 10% After Promoters Sell 19.6 Lakh Shares

Pharmaceutical manufacturing lab with a stock chart on a glass wall

Synopsis: Laurus Labs shares fell as much as 10% to ₹2,190 on Monday, their sharpest fall in nearly two years, after insider-trading disclosures showed founder and CEO Satyanarayana Chava and promoter entity Leven Holdings sold 19.64 lakh shares on 11 November, the day the stock hit a record ₹2,488.

Shares of Hyderabad-based drugmaker Laurus Labs fell as much as 10% to ₹2,190 on the NSE on Monday, 16 November 2026. The fall followed disclosures filed with the stock exchanges under SEBI’s insider trading regulations, which showed two promoter entities selling shares in the open market.

Who sold and how much

  • Satyanarayana Chava, founder and chief executive, sold 14,85,445 shares on 11 November. He now holds 15,70,000 shares, about half of his earlier personal holding of roughly 30.55 lakh shares.
  • Leven Holdings, the promoter entity linked to executive director and CFO V V Ravi Kumar, sold 4,78,836 shares on the same day and holds 62,05,000 shares after the sale.
  • Together the two sold 19,64,281 shares. Media reports have put the value at roughly ₹487 crore.

The disclosures do not give a reason for the sales. The transactions took place on 11 November, when the stock touched its all-time high of ₹2,488.

Heavy trading, sector also weak

Trading volumes nearly doubled from the average, with about 6.3 million shares changing hands on the NSE and BSE combined, Business Standard reported. The selling came on a weak day for drug stocks: the Nifty Pharma index fell 1.53%, the worst sectoral performance on the NSE, even as the Nifty 50 closed 0.58% higher.

Context

Laurus Labs has been one of 2026’s strongest pharma stocks, nearly doubling this year on the back of its contract development and manufacturing (CDMO) business. Promoter selling near record highs tends to draw attention from investors because insiders have the best view of a company’s prospects, although promoters also sell for personal, tax or diversification reasons. The company has not commented publicly on the sale.

For more on the sector’s run this year, see how Nifty Pharma beat the market in 2026, and for the day’s broader action, our 16 November market close report.

Image credit: AICreate / EQMint.

Sources

Disclaimer: This article is for information purposes only and is not investment advice.

For more such information, visit EQMint

Join our WhatsApp channel for timely updates: Whatsapp

Advertisement

The market and startup brief

Join 50,000+ professional readers.

eqmint